Sanara MedTech, Biomimetic Innovations provide update on OsStic

Sanara MedTech (SMTI), together with Biomimetic Innovations, provided an update on progress related to their strategic alliance. In addition, Sanara reaffirmed its plans to introduce OsStic Synthetic Injectable Structural Bio-Adhesive to the U.S. commercial market in the first quarter of 2027, following anticipated clearance by the U.S. Food and Drug Administration, FDA, to support reduction and provisional fixation treatment of the more than 100,000 peri-articular fractures occurring annually nationwide. Seth Yon, Sanara’s President and Chief Executive Officer, commented “OsStic exemplifies our commitment to bringing truly innovative solutions to the surgical market. By working closely with BMI, we’re expanding our portfolio through our License and Distribution Agreement with BMI to address critical unmet needs in orthopaedic care and strengthen our position as a leader in surgical innovation.”